How to Sequence Global and India Market Entry for Medical Devices Without Creating Regulatory Rework

One of the most avoidable and expensive mistakes in Medical Device commercialisation is Regulatory rework — the process of going back to redo documentation, testing, or submissions 

because the original data was not designed to serve multiple regulatory frameworks. Companies that plan their global market entry sequence intelligently can avoid doing the rework/resubmission entirely. 

Many companies discover the problem only after completing their first major submission, by which time significant time, effort, and financial resources have already been invested

.

This final article in the CliniExperts Medical Device Content Series focuses on practical strategy: how to sequence your global and India regulatory submissions to minimise rework, maximise documentation reuse, and achieve the fastest possible path to multiple markets.

The Root Cause of Regulatory Rework

Regulatory rework typically arises from one of three planning failures:

1. Documentation designed for one framework only: Technical files, Clinical Evaluation reports, or labelling prepared exclusively for FDA or EU MDR without considering what other frameworks require — and without building in the flexibility to adapt them
2. Testing gaps discovered later: Biocompatibility, electrical safety, or performance tests conducted to one standard (e.g., IEC 60601-1 with US amendments) that require re-testing to meet a different standard or edition required by the second market
3. India treated as an afterthought: Companies that file in the US or EU first and then approach India as a separate, later-stage exercise frequently discover that the documents they produced for their primary market need significant reworking to meet CDSCO’s format and content requirements

The most important insight for avoiding rework is this: regulatory frameworks share far more in common than they differ. A technical file built to EU MDR standards, with properly structured clinical evaluation, ISO 14971 risk management, and ISO 13485 QMS documentation, can address a significant proportion of CDSCO’s requirements, often reducing the need for substantial new documentation.

. The gap is bridgeable — but only if you know where it is before you start writing.

The Overlapping Core: What All Major Frameworks Share

Before planning your sequence, it helps to understand what documentation is shared across FDA, EU MDR, UK MHRA, and CDSCO:

Table 1

The Key Differences That Drive Rework

Understanding the differences — rather than the commonalities — is where rework prevention happens:

4. Clinical evaluation format: 
5. EU MDR requires a structured Clinical Evaluation Report (CER) in accordance with Article 61, Annex XIV, and MEDDEV 2.7/1 Rev. 4. FDA 510(k) submissions require a different approach and format for presenting supporting clinical and technical information
6.  FDA 510(k) requires a different format (summary of technical information or detailed information). CDSCO accepts both, but the framing and structure need adaptation.
7. Electrical safety standards edition: Many jurisdictions accept testing conducted in accordance with recognised standards and applicable national deviations

. Acceptance of IEC 60601-1 editions varies by jurisdiction and transition period. Manufacturers should verify current FDA-recognised consensus standards and applicable EU harmonised standards, and where possible conduct testing to the most current internationally accepted edition and applicable national deviations

8. Test to the most demanding standard first.
9. Labelling requirements: Each market has specific mandatory labelling fields. Build a master label that accommodates all markets’ mandatory elements — then create market-specific versions from that master.
10. QMS evidence format: FDA QMSR, EU MDR ISO 13485, and CDSCO Schedule V are harmonised in substance but differ in audit evidence formatting. A single ISO 13485-compliant QMS with good documentation practices satisfies all three.
11. Post-market surveillance plan depth: EU MDR requires the most detailed PMSP. Producing an EU MDR-compliant PMSP first gives you a document that can be adapted (simplified) for FDA and CDSCO — not the other way around.

Recommended Sequencing Strategy for India-Inclusive Global Launch

Phase 1: Pre-Submission Planning (Months 1–3)

1. Identify all target markets and their specific regulatory requirements
2. Conduct a gap analysis of your existing documentation against the requirements of all target markets simultaneously
3. Identify shared testing standards and confirm which edition/version satisfies the most demanding market requirement — test to that standard
4. Design your technical file and clinical evaluation architecture to be modular — core documents usable across markets with market-specific annexes
5. Appoint regulatory consultants or Authorised Agents in all target markets — including India — before dossier preparation begins. 

Phase 2: Core Documentation Build (Months 3–9)

6. Develop technical documentation to EU MDR requirements — this is the most comprehensive and covers the core requirements of all other frameworks
7. Conduct risk management under ISO 14971:2019 — accepted by all four frameworks
8. Complete clinical evaluation under MEDDEV 2.7/1 Rev 4 — adaptable for FDA and CDSCO
9. Prepare your ISO 13485-compliant QMS documentation — applicable to EU MDR, UK MHRA, and CDSCO
10. Run all testing to the most stringent applicable standard — verify acceptability for all target markets before finalising test reports

Phase 3: Market-Specific Submissions (Months 6–18, overlapping)

11. File your primary market submission (FDA or EU MDR, depending on commercial priority)
12. Simultaneously prepare your India MD-14 or MD-23 dossier — leveraging the technical file, CER, and QMS documents already produced in Phase 2
13. File CDSCO application within 1–2 months of your primary market submission — not after approval
14. Pursue UK MHRA registration as a third regulatory track if the UK is a commercial priority 
15. Use approval in primary market as a reference when communicating with CDSCO — and reference the pending approval status proactively

Filing in India while your primary market application is pending — not after it is approved — is a strategy many companies overlook. CDSCO review timelines can vary significantly depending on device classification, application completeness, regulatory pathway, and agency workload.

. If you wait for FDA or CE approval before filing in India, you add that entire timeline to your India launch date. Filing in parallel means both approvals may land within months of each other.

India-Specific Documentation Adaptations

When adapting your core technical file for the India CDSCO MD-14 or MD-23 application, the following specific adaptations are typically required:

12. Certificate of Free Sale: Obtain a Certificate of Free Sale or equivalent market authorisation evidence from the country of origin, where applicable, in accordance with CDSCO requirements. 
13. Authorised Agent appointment: A letter appointing your Indian Authorised Agent, compliant with CDSCO’s format requirements
14. Labelling review: Verify that your India label includes all mandatory fields under MDR 2017 Schedule II — some fields (e.g., Net Quantity in metric units, manufacturer’s India import address) differ from FDA and EU MDR requirements
15. Clinical data Indian relevance section: For MD-23 (New Device), prepare a brief Indian patient population relevance assessment explaining why international clinical data is applicable to the Indian population
16. SUGAM portal formatting: CDSCO’s online submission system has specific document format, file size, and naming requirements — prepare your submission package accordingly

Conclusion: The India Opportunity Awaits the Prepared

India is the world’s fifth largest economy, a rapidly growing Medical Device market, and a country where the government is actively encouraging both domestic manufacturing and foreign device Imports to meet the healthcare needs of 1.4 billion people. The Regulatory pathway is structured, navigable, and — for companies with strong international approvals — significantly faster than many expect.

The companies that capture India’s Medtech opportunity earliest will be those that plan their global Regulatory strategy with India integrated from the start — not those that add India as an afterthought after their primary market approval. 

Much of the underlying Regulatory and technical documentation can be leveraged across multiple jurisdictions when developed strategically from the outset. The strategic advantage of early India entry is entirely unique.